A Case of Pregnancy Despite Infertility From Congenital Plasminogen Deficiency
January 6th 2021Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the details of a patient who had a successful pregnancy despite documented infertility due to congenital plasminogen deficiency.
Watch
Ambulatory Care Pharmacists in Diabetes Education Centers Can Help Improve Diabetes Outcomes
January 5th 2021The objective of the study was to evaluate the impact of the ambulatory care pharmacist intervention on A1C changes in patients with uncontrolled type 2 diabetes mellitus (T2DM) during a 2-year period at the diabetes education center.
Read More
Managing Therapies in Patients With Cervical and Endometrial Cancers
January 5th 2021Pharmacists play a key role in educating patients on risk factors for cervical and endometrial cancers and can assist with treatment decisions, and management of potential adverse effects in patients with these cancers.
Read More
Common Manifestations of Congenital Plasminogen Deficiency and Their Impact on Patient Outcomes
December 24th 2020Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, describes common manifestations of congenital plasminogen deficiency and their impact on patient outcomes.
Watch
The Causes and Characteristics of Congenital Plasminogen Deficiency
December 24th 2020Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses why congenital plasminogen deficiency is often underdiagnosed and describes the causes and characteristics of the disorder.
Watch
Understanding the 340B Prime Vendor Program and Supporting Stakeholders During COVID-19
December 15th 2020Under the 340B Prime Vendor Program, the Prime Vendor has several functions that it carries out to support stakeholders in operating and navigate the field so that they can effectively achieve lower 340B drug pricing for those who need it most.
Read More
Utilizing Education and Machine Learning to Establish an Opioid Prescription Stewardship Program
December 14th 2020Monitoring outpatient prescribing patterns has been a major challenge for the Lifespan health system in Rhode Island, since it has over 1.5 million electronic prescriptions written annually.
Read More
Obtaining Real-World Disease, Demographic Data on Myelofibrosis
December 11th 2020Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about why data are limited in myelofibrosis.
Read More
The Cardiorenal Benefits, Risks of Treating Type 2 Diabetes With SGLT2 Inhibitors
December 11th 2020There are compelling reasons to use sodium-glucose cotransporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.
Read More
New Data Reinforce Long-Term Benefit of Emicizumab for Patients With Hemophilia A
December 11th 2020The data presented at ASH 2020 build on results previously observed in the pivotal HAVEN clinical trial among adults, adolescents, and children with hemophilia A, with and without factor VIII inhibitors.
Read More
Unfounded Preventions, Treatments for COVID-19 and the Pharmacist Role in Educating the Public
December 11th 2020The objective of the study was to increase awareness among pharmacists about products for which unfounded claims have been made regarding prevention of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infections.
Read More
Making Treatment Decisions for Patients with Myelofibrosis
December 10th 2020Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about factors in treatment decisions for patients with myelofibrosis.
Watch